Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer ...

Dupixent nears EU approval for rare skin disease prurigo nod... Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising ... rare and highly debilitating skin disease. The two companies are still ...

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both ...

a neuroimmune cytokine that drives multiple disease mechanisms in prurigo nodularis. 3,4,8 The U.S. FDA has also accepted for review Galderma’s Biologics License Application for nemolizumab for ...